Leadership | CareDx

Executive Team

Reginald Seeto, MBBS

CHIEF EXECUTIVE OFFICER & PRESIDENT

Dr. Seeto is an experienced leader and has held executive leadership roles in both biotech and large pharma and across a broad range of functions. Before joining CareDx, Dr. Seeto was Chief Operating Officer at Ardelyx leading pre-launch efforts for tenapanor and corporate development where he completed a series of partnerships. Prior to this, Dr. Seeto worked at AstraZeneca/Medimmune and was a member of the MedImmune Executive Team. His responsibilities included leading corporate development and strategy, global strategic marketing and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. He started his career as a physician, during which time he performed a medical rotation in a renal transplant unit, before joining McKinsey and Company.

Abhishek Jain

CHIEF FINANCIAL OFFICER

Abhishek became CareDx’s Vice President, Corporate Controller in August 2021. Prior to joining the Company, he spent the last 20 years at Agilent Technologies, Inc., a global leader in the life sciences, diagnostics and applied chemical markets, in a series of finance and customer-facing roles of progressing responsibility. In his last role at Agilent as an Associate Vice President II, Controller-Sales and Marketing, he drove above market growth for a $5B business. He has extensive knowledge in driving channel strategy, expanding margins, scaling operations, and leading global teams. Mr. Jain is a member of the Institute of Chartered Accountants of India.

Alexander L. Johnson

PRESIDENT OF PATIENT & TESTING SERVICES

Alex Johnson brings broad international business experience in pharma and clinical diagnostics to CareDx. Prior to joining the company, Alex was Chief Operating Officer of BioGraph 55, a venture-backed immuno-oncology drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. From 2009 to 2014 he was with Novartis, where he held roles at Novartis Diagnostics, a global provider of blood screening solutions, and Novartis M&A, based in Basel, Switzerland, where he led acquisitions in oncology and diagnostics. Prior to Novartis, Alex was with UBS Investment Bank in the Global Healthcare Group. Alex studied economics at Union College (N.Y.) and received his MBA in finance from Columbia Business School.

Abraham Ronai

CHIEF ADMINISTRATIVE & LEGAL OFFICER AND SECRETARY

Abraham Ronai brings over 20 years of experience in the legal, compliance, and intellectual property fields with a focus on the life-science, medical device, and health care space. Before joining CareDx, Abraham spent 11 years at Getinge AB, a global medical technology company, where he held various leadership roles, including Global General Counsel. Prior to Getinge, Abraham worked at two well-respected law firms in Manhattan and at Datascope Corp., a Nasdaq-listed medical device company. Abraham also served as a professor for patent litigation at Concord Law School. He earned his Bachelor of Science in mechanical engineering from Cornell University and his Juris Doctor from the Benjamin N. Cardozo School of Law at Yeshiva University. Abraham is registered in-house counsel in Calif., and is admitted to practice law in N.Y. and N.J.

Marica Grskovic, PhD

CHIEF OPERATIONS OFFICER

Marica has spent the past two decades building and leading high-performing technology and product development teams. At CareDx, Marica has held roles of increasing leadership and management responsibilities and is currently accountable for strategy and operational oversight of the Cell Transplant Therapy business unit and Pharma Partnerships. Earlier in her career, Marica spearheaded the development of AlloSure^®, the first analytically and clinically validated cell-free DNA test developed specifically for transplant patients. Prior to CareDx, Marica was a founding scientist at the stem cell-based drug discovery platform technology company iPierian (acquired by BMS), and its spin out, True North Therapeutics (acquired by Bioverativ).

Marica completed her post-doctoral fellowship on gene regulation in stem cells at University of California San Francisco and holds a PhD in molecular biology and biochemistry from European Molecular Biology Laboratory and University of Heidelberg, Germany.

Mickey Kim, MD

SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT & HEAD OF GLOBAL PRODUCT

Mickey brings over 25 years of corporate development, strategy and innovation experience in the health care delivery, health care IT, and medical products sectors. Before joining CareDx, Mickey was the Senior Vice President of Research and Commercialization at Inova Health System, where he led all aspects of commercialization activities, and the President of the Inova Translational Medicine Institute, a research and development organization focused on applied genomics. Prior to Inova, he worked at AstraZeneca/MedImmune as a member of MedImmune’s Partnering & Strategy Leadership Team as a healthcare venture capitalist, and he also worked as a strategy consultant with McKinsey and Company. Mickey holds several degrees; he earned his Medical Doctor degree from the Northwestern University Medical School; his Master of Business Administration from the J.L. Kellogg Graduate School of Management, Northwestern University; and his Bachelor of Arts from the University of Chicago.

Kashif Rathore

CHIEF OF PATIENT AND DIGITAL SOLUTIONS

Kashif Rathore has over 22 years of executive management experience in the healthcare and information technology industry. Before joining CareDx, Kashif was Vice President, Interoperability at Cerner Corporation, a global provider of electronic health records and population health solutions. He headed the expansion of the unit with worldwide growth in its interoperability business. Having served on the Board of Directors for CommonWell Health Alliance and Superscripts Advisory Council, he brings industry perspective that enables him to engage leaders across the industry to build alignment. Kashif holds a Bachelor of Business Administration degree in Management Information Systems from the University of Central Oklahoma, and a Bachelor of Arts degree in Mathematics from the University of Punjab. Kashif earned an Executive MBA from University of Missouri, Kansas City.

Srini Srinivas, MD

SENIOR VICE PRESIDENT, CLINICAL OPERATIONS AND MEDICAL AFFAIRS

Titte R “Srini" Srinivas, who has been serving at CareDx as VP, Digital Development and Clinical Integration will take over as Senior Vice President, Head of Medical and Clinical Operations (Interim), effective November 1, 2022. He is known in the transplant community for working tirelessly as the medical director at several kidney transplant programs including the Medical University of South Carolina (MUSC), Intermountain and University Hospitals in Cleveland. His research portfolio spans transplant outcomes, clinical trials of immunosuppression, biomarkers, renal allograft pathology, population health, and artificial intelligence applied to transplant outcome prediction. Prior to joining CareDx, Srini was the Chief, Division of Nephrology and Hypertension, University Hospitals, and Clinical Professor of Medicine at Case Western Reserve University, Cleveland.

Senior Leadership Team

Jarrod Borkat

SENIOR VICE PRESIDENT, HEAD OF MARKETING & PORTFOLIO OPERATIONS

Jarrod Borkat brings 22 years of global sales, marketing and business development experience to CareDx. Prior to joining CareDx in 2021, Jarrod served as vice president of corporate strategy at Emergent BioSolutions, a $1 billion life sciences company focused on developing vaccines and therapeutics for public health threats. While in this role, Jarrod also served on the Maryland Governor’s Life Science Advisory Board and was a board director for BioHealth Innovation and the Maryland Technology Council. Before Emergent, Jarrod held several leadership positions at MedImmune/AstraZeneca, including portfolio management, business development & licensing and government, non-government organizations and academic strategic partnerships. He spent the first half of his career at Boehringer Ingelheim Pharmaceuticals, where he started as a pharmaceutical sales representative and rose through the marketing ranks to become the U.S. commercial lead for BI’s HIV franchise and global marketing lead for its CNS franchise. Jarrod is recognized in the life sciences industry for speaking at conferences throughout the nation, including SXSW, AUTM, BIO, and The BioHealth Capital Region Forum. Jarrod graduated from University of Georgia with a bachelor’s in biology and has an MBA from Kennesaw State University.

Pauline Callinan, PhD

VICE PRESIDENT, BUSINESS DEVELOPMENT

Pauline brings over 15 years of business development and licensing experience in the biopharmaceutical and academic tech transfer sectors. Before joining CareDx, Pauline was the Vice President of Business Development & Strategy for Sensei Biotherapeutics. Prior to Sensei Bio, she worked for AstraZeneca/MedImmune in the Partnering and Strategy Group, and Johns Hopkins Technology Transfer, as Portfolio Director, Life Sciences. Before that, Pauline was a post-doc at the Johns Hopkins School of Medicine, where she studied the epigenetics of human disease. She has published a book chapter, review articles, and first-authored publications in peer reviewed journals.

Pauline holds a PhD degree in biochemistry from Louisiana State University, and a BSc in human biology with honors from Loughborough University in the United Kingdom.

Kim Clark-Langone, PhD

VICE PRESIDENT, NEW PRODUCT DEVELOPMENT

Kim has spent over 20 years leading multi-disciplinary teams focused on biomarker discovery and the development of molecular diagnostics. Kim comes to CareDx from Talis Biomedical Corp., where she was Senior Director, Assay Development. Prior to Talis, Kim spent 19 years at Genomic Health Inc./Exact Sciences Corp., where she held various roles of increasing responsibility, including Senior Director, Assay and Informatics Development. There, she was involved in the development and validation of a suite of OncotypeDX^® gene expression tests for breast, colon and prostate cancer and led the development and validation of a liquid biopsy mutation panel, Oncotype SEQ^™ Liquid Select. Recently at CareDx, Kim has led assay improvements for AlloSure^®️ and the development of XenoSure^™, a donor-derived cell-free DNA (dd-cfDNA) assay for xenotransplant recipients. Kim received her BSc in genetics and her Ph.D. in mitochondrial genetics at the University of Newcastle upon Tyne, England, and completed her post-doctoral studies on the role of mitochondrial DNA dimers in cancer at Stanford University.

Hal Gibson

SENIOR VICE PRESIDENT, STRATEGIC PARTNERING

Hal Gibson brings 22 years of sales, marketing, and business development experience in transplant diagnostics to CareDx. Prior to CareDx, Hal was at One Lambda, Inc., where he was a leader in launching and driving early clinical research and commercial adoption of single antigen bead technology for detection of anti-HLA donor specific antibodies. Post-acquisition of One Lambda by Thermo Fisher Diagnostics, he served as a senior leader in its Transplant Diagnostics business, where he helped drive clinical strategy and business development. Hal received a Bachelor of Science in biology from the University of Tampa.

Julian Husbands, MD

VICE PRESIDENT, COMMERCIAL OPERATIONS - TESTING SERVICES

Julian has more than two decades of experience spanning the healthcare spectrum, as both a clinician and through his work in multiple corporate functions with different types of companies. At Apria Healthcare, he led the creation and execution of the most successful initiative ever at Apria — a COPD clinical management program that grew to over $200M annually in five years with a 60% reduction in readmissions. At Edwards Life sciences, he had strategic and line management responsibilities within the Critical Care and Surgical Heart Valve businesses. Julian’s background also includes management consulting with McKinsey and Company, and he trained as a general surgeon at the University of Pennsylvania. Julian received his Bachelor of Science in business administration from the University of California, Berkeley and his Doctor of Medicine from the University of Pennsylvania.

Ashish Kothari, MD

VICE PRESIDENT, MEDICAL AFFAIRS

Ashish Kothari has more than 20 years of experience in clinical development, medical affairs, strategy and business development that spans across academia, industry, and investment management. Ashish started his academic career as a spine surgeon and managed patients and taught medical students for 10 years. Following that, he held multiple leadership roles in strategy, medical affairs, and clinical development across cell therapy, oncology, neurology, infectious disease, autoimmunity, and transplant, including roles at CareDx, Genentech/Roche, McKinsey, and Royalty Pharma. He cites CareDx’s commitment to transplant patients, focus on innovation, can-do attitude, and singular focus on improving transplant patient outcomes as the elements that fuel his passion to work with his amazing team to drive the science, enhance the standards of medical practice, and ultimately, improve patients’ lives.

Ashish conducted research in tissue engineering and cell therapy at the Harvard Medical School and MIT’s Health Sciences and Technology (HST) program. He earned an MBA from the MIT-Sloan School of Management, where his thesis focused on the impact of research, innovation, and regulatory strategy on the global launch of medical technologies. He is also a CFA charter holder from the Chartered Financial Analysts’ Institute.

Greg Quinn

SENIOR VICE PRESIDENT, GLOBAL PATIENT SERVICES

Greg has more than 15 years of sales and management experience in healthcare and molecular diagnostics. In additional to his professional experience, as the father of a heart transplant recipient, Greg also has a deep understanding, appreciation, and passion for patient care. His daughter, Madelyn, had a heart transplant when she was 22 months, and now, almost 9, she is now thriving. Prior to CareDx, Greg was a senior leader at Boston Heart and SpectraCell Laboratories. Greg holds a master's of Business Administration from San Jose State University.

Marco Scheller

SENIOR VICE PRESIDENT, CLINICAL OPERATIONS

Marco brings over 30 years of global experience in therapeutics and diagnostics with mid- and large-cap pharma companies in roles spanning strategy, new product development, marketing, analytics, business development and operations, both commercial and clinical. Most recently at CareDx, Marco led the R&D Program Management Office, supporting the development of various new products and services, including AlloMap Kidney and KidneyCare. Prior to joining CareDx, Marco led the strategy and new products function at Ferring. Earlier in his career, Marco worked at McKinsey & Co., advising healthcare clients around the world. Besides transplantation, Marco’s therapeutic area experience includes cardiovascular, CNS, women’s health and oncology. Marco holds a master’s in pharmaceutical process engineering from ETH Zurich and an MBA in finance from Columbia Business School.

Robert N. Woodward, PhD

SENIOR VICE PRESIDENT, RESEARCH AND DEVELOPMENT

Dr. Robert Woodward has led research and development projects in transplant diagnostics and gene expression discovery for over 20 years. Most recently at CareDx he was responsible for the bioinformatics, biostatistics, and laboratory teams that developed and validated AlloSure®, an application of cell-free DNA to solid organ transplantation. Earlier in his career, he initiated biomarker discovery efforts with BioCardia and XDx and subsequently led the laboratory development of AlloMap, a gene expression test that has become an integral component of precise patient care in heart transplantation. During a post-doctoral fellowship at the Gladstone Institutes and University of California San Francisco, Dr. Woodward developed unique methods for analysis of gene regulation in vivo to study atherosclerosis. Following a bachelor’s degree in biology from Missouri State University, Dr. Woodward earned his Ph.D. in physiology at the University of Missouri-Columbia where he described the effects of a new transcription factor in the coordinate regulation of gene expression in response to steroids.

Board of Directors

Michael D. Goldberg

CHAIRMAN

Michael Goldberg has served as chairman of board or lead independent director since November 2011. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as chairman until August 2001 and as chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as chief executive officer until its sale to Bristol-Myers Squibb in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm, Sevin Rosen Management Company, from 1985 to 1987, where he established the firm’s life science practice, and was director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the board of directors of numerous companies in the biotech and health sciences industry, and currently serves as executive chairman of DNAnexus, Inc. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic, and public policy institutions in biotechnology and finance, including the board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the board of the Western Association of Venture Capitalists, the advisory boards of the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.

George Bickerstaff

George W. Bickerstaff, III has served as a member of our board of directors since April 2014. Mr. Bickerstaff is currently the managing director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to that Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including chief financial officer of Novartis Pharma AG from October 2000 to May 2005. Previously, George held senior finance and operating roles with various global companies including, IMS, Dun & Bradstreet and General Electric. Mr. Bickerstasff received a BS in engineering and a BA in business administration from Rutgers University in 1978.

Dr. Fred Cohen, MD, DPhil

Fred E. Cohen has served as a member of our board of directors since January 2003. He is a founder and senior managing director of Vida Ventures, a biotechnology venture capital group. Dr. Cohen is a senior advisor of TPG, a global private equity firm. Dr. Cohen joined TPG in 2001, and serves as head of TPG’s biotechnology group. Dr. Cohen was a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco from 1988 to 2016. Dr. Cohen has played a role on the boards of directors or scientific advisory boards of a variety of biotechnology companies. He currently serves on the board of directors of Veracyte, Inc., BioCryst Pharmaceuticals, Inc., and Five Prime Therapeutics, Inc., as well as multiple other private and public companies. He received his MD from Stanford University, his DPhil in Molecular Biophysics from Oxford University as a Rhodes Scholar, and his BS in Molecular Biophysics and Biochemistry from Yale University. Dr. Cohen was elected to the Institute of Medicine and the National Academics in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen also serves a fellow of the American College of Physicians since 1989, a member of the American Society for Clinical Investigation and the Association of American Physicians and is the recipient of several awards and honors including the Burroughs-Wellcome New Initiatives in Maleria Award, the LVMH Science Pour L’Art Price (shared with Stanley Prusiner), and Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation.

Grace E. Colón, PhD

Grace E. Colón has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company developing therapeutics for cardiovascular conditions since 2013. In addition to her role on the board at CareDx, she is also Executive Chairman (formerly CEO) of ProterixBio and sits on the boards of the MIT Corporation and the Biotechnology Innovation Organization. Previously, she served on the boards of Paradigm Diagnostics (acquired by Exact Sciences), Perceptimed, Cocoon Biotech, and on the advisory board of the Miller Center for Social Entrepreneurship at Santa Clara University. Previously, she was a partner at New Science Ventures, a New York based venture capital firm. From 2010-2012, she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. At Gilead she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was Vice President, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., and an engineer with Merck & Co. in France and in Rahway, NJ. Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow, and holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.

Chris Cournoyer

Chris Cournoyer is presently a strategic advisor to QIAGEN and prior to that served as the Chairperson and Chief Executive Officer for N-of-One. Chris led the transformation of N-of-One’s patient concierge business to a leading molecular decision support company in oncology. Under her leadership she raised capital, created the digital strategy for interpreting molecular diagnostic tests and led the strategic sales process resulting in a successful sale to QIAGEN in 2019. Prior to joining N-of-One, Chris was the Vice President of Clinical Analytics for Optum responsible for clinical EHR solutions and the clinical decision support solutions. Prior to joining Optum through the acquisition of Picis in 2010, Chris was the President and COO for Picis, Inc., a global leader in the Healthcare IT market, offering digital EHR solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Previous to Picis, Chris was responsible for all analytical solutions serving the retail industry at Harte Hanks. From 1995- 2001, Chris held technology roles at Lotus as Chief Information Officer and at IBM where she was Vice President of Global Business Transformation responsible for the order to cash operations and for the Information Technology function for an $8B software business for IBM. Chris has provided technology expertise to three public boards including Stride Rite, GTECH, and BJ’s Wholesale group and has been a director for Emerson Hospital. Chris holds a B.S in Business Administration, University of Massachusetts, an MA Economics, Northeastern University and has attended MIT’s Executive Education Program.

William Hagstrom

William Hagstrom has served as a member of our board of directors since March 2015. He is currently the founder and CEO of Octave Bioscience, an early stage molecular diagnostics company focused on neurodegenerative diseases and conditions. In 2007, Mr. Hagstrom secured financing for Crescendo Bioscience, a specialty diagnostics company focused on autoimmune and inflammatory diseases managed by rheumatologists. Serving as president and chief executive officer, he led the development of the company’s product pipeline, operations infrastructure and commercial strategy. In 2014, Crescendo was acquired by Myriad Genetics as a wholly owned subsidiary. Prior to founding Crescendo Bioscience, Mr. Hagstrom was president of Alpha BioPartners, a strategic consulting firm for early stage biotechnology companies. While at Alpha, Mr. Hagstrom co-founded Biolytx Pharmaceuticals and Altheus Therapuetics. Mr. Hagstrom also served as interim CEO of Selexys Pharmaceuticals and Inoveon. Previous to this he was Chairman and CEO of UroCor, a specialty diagnostics company focused on urological cancers and complex diseases. Under Mr. Hagstrom’s leadership, the company was an Inc. 500 company from 1992, 1993, 1994 and 1995, before becoming public in 1996. Previously, Mr. Hagstrom held executive positions at some of the largest multinational healthcare companies in the world, including Becton Dickinson, American Hospital Supply and Baxter International, where he served as Vice President of the company’s billion-dollar scientific products division. Mr. Hagstrom has served on a variety of Boards over the last 15 years, including Prometheus Laboratories. Mr. Hagstrom received a BS degree in business management from Bob Jones University.

Peter Maag, PhD

Dr. Maag has served as CareDx President and CEO, Chairman and CEO or Executive Chairman since October 2012 until November 2021, and has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Peter was President of Novartis Diagnostics. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Peter also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he served as the Head of Strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Peter worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds a supervisory board position at Phoenix Pharma SE and serves on the board of the Personalized Medicine Coalition in Washington, DC. Peter studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany.

Reginald Seeto, MBBS

CHIEF EXECUTIVE OFFICER & PRESIDENT

Senator Art Torres (Ret.), JD

Senator Art Torres began serving on the CareDx Board of Directors in September 2021. He is the vice chair of the governing board of the California Institute for Regenerative Medicine, a public agency charged by the voters through Proposition 14 in 2020 to distribute $5.5 Billion in funding for stem cell research. He is also a member of the University of California Board of Regents and the Covered California board overseeing Obamacare.
A colon cancer survivor and passionate patient advocate, Torres is the vice chair on the board of One Legacy, an organ transplant foundation based in Southern California, where he has been a vocal supporter for organ transplant awareness in communities of color.
Torres began his career working alongside Cesar Chavez to fight against pesticide exposure that was killing and sickening farm workers in California. He later served for 20 years in the California legislature, chairing the State Assembly’s Health Committee, and then was elected as chair of the State Democratic Party, where he served from 1996 to 2009, making him the longest serving chair in our country’s history.
During his 20 years in the California Legislature, he chaired the Senate Insurance Committee, founded the Senate Toxics Committee and chaired the UC Admissions Committee. From 1974 to 1982, he served in the California State Assembly and in the California State Senate from 1982 to 1994. He also spent time as John F. Kennedy teaching fellow at Harvard University’s John F. Kennedy School of Government. He also was appointed as the University of San Francisco Diversity Scholar Visiting Professor. Senator Torres received his bachelor’s degree from UC Santa Cruz, and a J.D. from the UC Davis School of Law.

Hannah Valantine, MBBS, MD, MRCP

Hannah Valantine received her MBBS degree from London University, cardiology fellowship at Stanford, and Doctor of Medicine from London University. She was appointed Assistant Professor of Medicine, rising to full Professor of Medicine in 2000, and becoming the inaugural Senior Associate Dean for Diversity and Leadership, in 2004. She pursued a data-driven transformative approach to this work, receiving the NIH director’s pathfinder award. Dr. Francis Collins, NIH director, recruited her in 2014 as the inaugural NIH Chief Officer for Scientific Workforce diversity, and as a tenured investigator in the National Heart, Lung, and Blood Institute’s intramural research program where she established the laboratory of transplantation genomics. Dr. Valantine is a nationally recognized pioneer in her field, with over 200 peer-reviewed publications, patents, and sustained NIH funding. She was elected to the National Academy of Medicine in 2020 for both her pioneering research in organ transplantation and workforce diversity.